Business
ANGLE launch of Portrait Flex assay
ANGLE launch of Portrait Flex assay.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\n\n\n\n\nFor immediate release\n\n\n4 September 2023\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nLAUNCH OF PORTRAIT FLEX CIRCULATING TUMOR CELL ASSAY\n \nThe Portrait Flex assay provides tailored analyses performed as a service by ANGLE's Onc-ADaPT™ laboratories\n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumor cell (CTC) diagnostic solutions for the research and diagnostic oncology market, is pleased to announce the launch of its Portrait™ Flex CTC assay*. The assay is provided as a service from ANGLE's Onc-ADaPT™ GCP-compliant laboratories and conducted by an expert team with over 10 years' experience in CTC analysis.\n \nCTCs captured and harvested using ANGLE's Parsortix® technology are subsequently enumerated and characterised with the Portrait Flex assay. Samples are analysed using immunofluorescence staining for epithelial, mesenchymal, blood lineage and nuclear markers, with the opportunity to include an additional biomarker tailored to customer needs. Examples of clinically relevant CTC biomarkers that have been researched using Parsortix technology and published in peer-reviewed publications include HER2, PIK3CA, PD-L1, EGFR, BRAF, AR-V7 among others.\n \nThe Portrait Flex assay has an analytical sensitivity** of >93%, and an analytical specificity** of >95% for both epithelial and mesenchymal markers. Data from the analysis of clinical samples from 16 metastatic breast cancer patients identified CTCs in 81% of patients, with 38.5% of the CTC-positive patients having ≥1 CTC with high HER2 levels highlighting the capability to assess current HER2 status in breast cancer patients. Of the patients with CTCs, approximately half showed a mesenchymal only phenotype, while the others showed a mixed phenotype, highlighting the importance of Parsortix epitope-independent isolation of CTCs.\n \nCombining the use of the Parsortix technology and the Portrait Flex assay allows for testing that is specific to customer needs and can enhance their clinical trial evaluations. ANGLE is offering a flexible, full-service solution to help unlock precision medicine for patients.\n \nANGLE Chief Commercial Officer, Brett Swansiger, commented:\n\"I am pleased to announce the launch of our new Portrait™ Flex assay in our Onc-ADaPT™ clini...